Dendritic cells for type I diabetes

This study aims to assess the safety and efficacy of treating type I diabetes with autologous dendritic cells ex vivo with antisense phosphorothioate-modified oligonucleotides targeting the primary transcripts of the CD40, CD80 and CD86 co-stimulatory molecules. The dendritic cells were safely tolerated. and there were no discernible adverse events in any patient throughout the study. The dendritic cells upregulated the B220+ CD11c− B-cell counts.